Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants.
about
Respiratory Syncytial Virus Infection in High-risk Infants - an Update on Palivizumab ProphylaxisRisk factors associated with RSV hospitalisation in the first 2 years of life, among different subgroups of children in NSW: a whole-of-population-based cohort studyProduct review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.Association between respiratory syncytial viral disease and the subsequent risk of the first episode of severe asthma in different subgroups of high-risk Australian children: a whole-of-population-based cohort study.
P2860
Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Palivizumab in preventing resp ...... lization in high-risk infants.
@en
Palivizumab in preventing resp ...... lization in high-risk infants.
@nl
type
label
Palivizumab in preventing resp ...... lization in high-risk infants.
@en
Palivizumab in preventing resp ...... lization in high-risk infants.
@nl
prefLabel
Palivizumab in preventing resp ...... lization in high-risk infants.
@en
Palivizumab in preventing resp ...... lization in high-risk infants.
@nl
P2860
P356
P1476
Palivizumab in preventing resp ...... lization in high-risk infants.
@en
P2093
Bernhard Resch
P2860
P304
P356
10.1586/14737167.8.6.529
P577
2008-12-01T00:00:00Z